martes, 17 de febrero de 2026
Compass says its psilocybin drug helped patients with severe depression in two trials Results support FDA approval, but it’s unclear how competitive the treatment will be
https://www.statnews.com/2026/02/17/compass-pathways-comp360-psilocybin-severe-depression-trial-results/
By Elaine ChenFeb. 17, 2026
Elaine Chen, a national biotech reporter, is the co-author of The Readout, a newsletter about the business, science, and politics of biotech.
Suscribirse a:
Enviar comentarios (Atom)


No hay comentarios:
Publicar un comentario